Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIV200 Vaccine in Triple Negative Breast Cancer
NCT02593227Phase 2Completed
- Sponsor
- Marker Therapeutics, Inc.
- Start
- Apr 2016
- Primary completion
- Jul 2021
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of TPIV200 in triple-negative breast cancer (TNBC), sponsored by Marker Therapeutics, Inc.. Started Apr 2016; status: completed.
02
Drugs
TPIV200
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02593227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593227.